These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12682643)

  • 1. G-CSF for imatinib-induced neutropenia.
    Heim D; Ebnöther M; Meyer-Monard S; Tsakiris D; Linn M; Tichelli A; Gratwohl A
    Leukemia; 2003 Apr; 17(4):805-7. PubMed ID: 12682643
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
    Ota S; Musashi M; Kondo K; Toyoshima N; Toubai T; Onozawa M; Mori A; Hashino S; Tanaka J; Matsuno K; Imamura M; Asaka M
    Acta Haematol; 2006; 116(1):8-18. PubMed ID: 16809884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia.
    Jørgensen HG; Copland M; Holyoake TL
    Cancer; 2005 Jan; 103(1):210-11. PubMed ID: 15540243
    [No Abstract]   [Full Text] [Related]  

  • 6. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
    Fang B; Li N; Song Y; Han Q; Zhao RC
    Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
    Morita R; Hashino S; Sogabe S; Dazai M; Onozawa M; Izumiyama K; Kondo T; Ota S; Kobayashi S; Imamura M; Asaka M
    Rinsho Ketsueki; 2004 Oct; 45(10):1105-10. PubMed ID: 15553045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
    Zaucha JM; Wyrowinska E; Prejzner W; Calbecka M; Hellmann A
    Clin Lab Haematol; 2006 Jun; 28(3):208-10. PubMed ID: 16706939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular edema as a complication of treatment with imatinib.
    Shimazaki C; Ochiai N; Uchida R; Fuchida SI; Okano A; Ashihara E; Inaba T; Fujita N; Nakagawa M
    Leukemia; 2003 Apr; 17(4):804-5. PubMed ID: 12682642
    [No Abstract]   [Full Text] [Related]  

  • 10. [STI571: a new dimension in the treatment of chronic myeloid leukemia].
    Somers JA; Shamelian SO; Löwenberg B; Ossenkoppele GJ; Cornelissen JJ
    Ned Tijdschr Geneeskd; 2002 Jan; 146(3):128-32. PubMed ID: 11826673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
    Silver RT; Cortes J; Waltzman R; Mone M; Kantarjian H
    Haematologica; 2009 May; 94(5):743-4. PubMed ID: 19407320
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
    Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
    Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
    Lee JJ; Kim HJ; Kim YJ; Lee S; Hwang JY; Kim YL; Kim DW
    Leukemia; 2004 Sep; 18(9):1539-40. PubMed ID: 15284852
    [No Abstract]   [Full Text] [Related]  

  • 14. [Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
    Hochhaus A
    Dtsch Med Wochenschr; 2002 Mar; 127(9):451-6. PubMed ID: 11870560
    [No Abstract]   [Full Text] [Related]  

  • 15. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
    Salesi N; Bossone G; Della Longa G; Di Cocco B
    Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
    Hui CH; Goh KY; White D; Branford S; Grigg A; Seymour JF; Kwan YL; Walsh S; Hoyt R; Trickett A; Rudzki B; Ma DD; To LB; Hughes TP
    Leukemia; 2003 May; 17(5):821-8. PubMed ID: 12750692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
    Marin D; Marktel S; Foot N; Bua M; Goldman JM; Apperley JF
    Haematologica; 2003 Feb; 88(2):227-9. PubMed ID: 12604417
    [No Abstract]   [Full Text] [Related]  

  • 18. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R
    Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
    Simpson E; O'Brien SG; Reilly JT
    Clin Lab Haematol; 2006 Jun; 28(3):215-6. PubMed ID: 16706941
    [No Abstract]   [Full Text] [Related]  

  • 20. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
    Schoch C; Haferlach T; Kern W; Schnittger S; Berger U; Hehlmann R; Hiddemann W; Hochhaus A
    Leukemia; 2003 Feb; 17(2):461-3. PubMed ID: 12592348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.